Shire PLC (NASDAQ:SHPG) – Equities researchers at SunTrust Banks cut their FY2017 earnings per share (EPS) estimates for Shire in a research note issued to investors on Tuesday. SunTrust Banks analyst J. Boris now forecasts that the biopharmaceutical company will earn $15.07 per share for the year, down from their previous forecast of $15.10. SunTrust Banks also issued estimates for Shire’s Q4 2017 earnings at $3.90 EPS and FY2018 earnings at $15.90 EPS.
Shire (NASDAQ:SHPG) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.86 by $0.12. The business had revenue of $4.15 billion for the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.37 earnings per share.
Shire (SHPG) opened at $132.86 on Thursday. The firm has a market capitalization of $39,919.61, a P/E ratio of 24.88, a PEG ratio of 0.71 and a beta of 1.41. Shire has a twelve month low of $123.73 and a twelve month high of $192.15. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.
A number of large investors have recently added to or reduced their stakes in the business. Commerzbank Aktiengesellschaft FI lifted its stake in Shire by 22.1% during the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 375 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Shire by 6.2% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock worth $1,073,000 after purchasing an additional 381 shares in the last quarter. Pitcairn Co. lifted its stake in Shire by 26.5% during the third quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock worth $293,000 after purchasing an additional 401 shares in the last quarter. ETRADE Capital Management LLC lifted its stake in Shire by 6.9% during the fourth quarter. ETRADE Capital Management LLC now owns 7,212 shares of the biopharmaceutical company’s stock worth $1,119,000 after purchasing an additional 466 shares in the last quarter. Finally, Thompson Investment Management Inc. lifted its stake in Shire by 5.2% during the third quarter. Thompson Investment Management Inc. now owns 9,390 shares of the biopharmaceutical company’s stock worth $1,438,000 after purchasing an additional 468 shares in the last quarter. Institutional investors own 20.74% of the company’s stock.
WARNING: “FY2017 Earnings Estimate for Shire PLC Issued By SunTrust Banks (SHPG)” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/15/fy2017-earnings-estimate-for-shire-plc-issued-by-suntrust-banks-shpg.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.